Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Acta Neuropathol. 2015 May 6;130(1):77–92. doi: 10.1007/s00401-015-1436-x

Figure 2. Loss of function variants in OPTN and TBK1 reduce mRNA and protein expression.

Figure 2

(a) Relative OPTN mRNA expression levels normalized to RPLPO for cases A and B and 6 FTLD-TDP cases without mutations in OPTN and TBK1 are represented relatively to 4 control brains. (b) Representative western blot showing OPTN and GAPDH protein levels (left panel) in cases A and B, 4 FTLD-TDP cases without mutations in OPTN and TBK1 are 4 normal control brains. The relative quantification of OPTN protein (from 2 independent protein extractions) for cases A and B as well as FTLD-TDP cases without mutations in OPTN and TBK1 (n=6) and controls (n=6) is shown in right panel. (c) Relative TBK1 mRNA expression levels normalized to RPLPO for cases A and B and 6 FTLD-TDP cases without mutations in OPTN and TBK1 are represented relatively to 4 control brains. (d) Representative western blot showing TBK1 and GAPDH (left panel) for cases A and B, 4 FTLD-TDP cases without mutations in OPTN and TBK1 and 4 normal control brains. The relative quantification of TBK1 protein (from 2 independent protein extractions) for cases A and B as well as for 6 FTLD-TDP cases without mutations in OPTN and TBK1 (n=6) and controls (n=6) is shown in right panel. For all panels, the error bar +/− SEM is shown. n.s.: not significant after a Mann-Whitney test.